GlassScriptPhysician profile
Nour Zleik
NPI 1396185534
$8,239.12
in general payments reported to CMS, 2019-2025
23 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $243 · 2021: $1,218 · 2022: $883 · 2023: $1,691 · 2024: $2,788 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,588.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,002.77 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,808.33 | 2020-2025 | Tavneos, Enbrel, Otezla |
| Janssen Biotech, INC. | $1,631.77 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $764.51 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $535.68 | 2019-2025 | |
| Pfizer INC. | $300.15 | 2020-2024 | |
| Alexion Pharmaceuticals, INC. | $178.42 | 2023-2024 | Strensiq, Ultomiris |
| Fresenius Kabi USA, LLC | $153.49 | 2023-2024 | Idacio |
| Organon LLC | $152.14 | 2024-2025 | Renflexis, Hadlima |
| Aurinia Pharma U.S., INC. | $144.19 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $131.81 | 2019-2025 | Orencia |
| Genentech USA, INC. | $68.43 | 2021-2024 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.56 | 2023-2024 | Cyltezo, Ofev |
| Lilly USA, LLC | $61.37 | 2023-2024 | Taltz |
| Kiniksa Pharmaceuticals International, Plc | $48.36 | 2024 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $47.67 | 2023-2025 | Bimzelx, Cimzia |
| Radius Health, INC. | $38.75 | 2024 | Tymlos |
| Janssen Pharmaceuticals, INC | $30.33 | 2022 | |
| Sandoz INC. | $18.97 | 2024 | Hyrimoz |
| Alvogen INC | $18.06 | 2023 | Teriparatide |
| Sobi, INC | $14.98 | 2022 | |
| Depuy Synthes Sales INC. | $14.17 | 2024 | Monovisc, Orthovisc |
| Horizon Therapeutics Plc | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nour Zleik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.